Just a few months after Vir Biotechnology lost an emergency authorization for its COVID-19 antibody, Marianne de Backer ...

Shares of the battered biotech Vir Biotechnology were up more than 70% on Wednesday, as the company reported its first positive data since it executed a major pivot last summer. A hot stock during ...

Vir Biotechnology, Inc. (NASDAQ:VIR – Get Free Report) has received an average recommendation of “Moderate Buy” from the six ratings firms that are covering the stock, Marketbeat reports. One ...

In this article, we are going to take a look at where Vir Biotechnology, Inc. (NASDAQ:VIR) stands against the other stocks that are skyrocketing now. The market has started to favor smaller ...

Leerink Partners analyst Roanna Ruiz reiterated a Buy rating on Vir Biotechnology (VIR – Research Report) on January 13 and set a price target of $20.00. Discover outperforming stocks and invest ...

Vir Biotechnology's recent share price rally is driven by their promising cancer program, despite their primary focus on hepatitis management. The company's market cap has surged past $1 billion ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Irhythm Technologies (IRTC – Research Report), Vir ...